Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 5 of 5 clinical reviews.
Denosumab treats giant cell tumor of bone (GCTB), but only the Xgeva formulation (120 mg) carries FDA approval. Learn the evidence, dosing, risks, and why Prolia (60 mg) is not interchangeable.
Read clinical reviewA clinical evidence summary of denosumab (Prolia/Xgeva) use in bone metastases, including FDA-approved vs. Off-label distinctions, key trial data, dosing differences, and guideline recommendations.
Read clinical reviewDenosumab is FDA-approved for bone metastases as Xgeva (120 mg), not Prolia (60 mg). Learn the clinical evidence, dosing differences, risks, and why the brand distinction matters for cancer patients.
Read clinical reviewDenosumab is FDA-approved as Xgeva for giant cell tumor of bone, but Prolia is the osteoporosis formulation. This evidence summary covers trial data, dosing, outcomes, and the critical brand distinction clinicians and patients should understand.
Read clinical reviewDenosumab is FDA-approved for giant cell tumor of bone under the brand Xgeva, not Prolia. Learn the clinical evidence, dosing differences, monitoring protocols, and why the brand distinction matters.
Read clinical review